Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
Ablation Techniques
/ methods
Adrenal Gland Neoplasms
/ complications
Antineoplastic Combined Chemotherapy Protocols
/ classification
Combined Modality Therapy
/ methods
Endocrine Surgical Procedures
/ methods
Humans
Immunotherapy
/ methods
Neoplasm Metastasis
Paraganglioma
/ complications
Paraneoplastic Endocrine Syndromes
/ therapy
Pheochromocytoma
/ complications
Radiopharmaceuticals
/ administration & dosage
catecholamines
metastatic paraganglioma
metastatic pheochromocytoma
radiopharmaceuticals
surgery
tyrosine kinase inhibitors
Journal
Best practice & research. Clinical endocrinology & metabolism
ISSN: 1878-1594
Titre abrégé: Best Pract Res Clin Endocrinol Metab
Pays: Netherlands
ID NLM: 101120682
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
7
11
2019
medline:
6
11
2020
entrez:
6
11
2019
Statut:
ppublish
Résumé
Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare neuroendocrine tumors. Most patients present with advanced disease that is associated with manifestations of catecholamine release. Surgical resection of the primary tumor and ablative therapies of metastases-whenever possible-may improve clinical outcomes and, perhaps, lengthen the patient's overall survival. Significant steps in understanding the genetic alterations linked to MPPGs and scientific progress made on cancers that share a similar pathogenesis are leading to the recognition of potential systemic therapeutic options. Data derived from clinical trials evaluating targeted therapies such as tyrosine kinase inhibitors, radiopharmaceuticals, immunotherapy, and combinations of these will likely improve the outcomes of patients with advanced and progressive MPPGs. Exemplary of this success is the recent approval in the United States of the high-specific-activity iodine
Identifiants
pubmed: 31685417
pii: S1521-690X(19)30105-8
doi: 10.1016/j.beem.2019.101354
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101354Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.